Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1986 1
2003 1
2007 2
2008 1
2009 2
2010 2
2011 3
2012 3
2013 3
2014 3
2015 3
2017 3
2019 2
2020 2
2021 3
2022 4
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Reply to Viel.
Recknor C, Hansen SG, Gaylis NB, Tiwary M, Sacha JB, Yang OO. Recknor C, et al. Among authors: gaylis nb. Clin Infect Dis. 2022 Oct 12;75(8):1486-1487. doi: 10.1093/cid/ciac390. Clin Infect Dis. 2022. PMID: 35819204 No abstract available.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
Patient Perspectives on Intravenous Biologics for Rheumatologic Disease.
Grisanti L, Kwiatkowski A, Dyrda P, Field E, Grisanti J, Hatem J, Dehoratius RJ, Gaylis N. Grisanti L, et al. Among authors: gaylis n. Arthritis Care Res (Hoboken). 2019 Sep;71(9):1234-1242. doi: 10.1002/acr.23758. Epub 2019 Aug 7. Arthritis Care Res (Hoboken). 2019. PMID: 30221490
41 results